Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials ; volume:22 ; number:1 ; day:26 ; month:1 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cancer ; 22, Heft 1 (26.1.2022), 1-8, 12.2022
- Urheber
-
Grayling, Michael J.
McMenamin, Martina
Chandler, Robert
Heer, Rakesh
Wason, James M. S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09227-7
- URN
-
urn:nbn:de:101:1-2022050620222985573762
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Grayling, Michael J.
- McMenamin, Martina
- Chandler, Robert
- Heer, Rakesh
- Wason, James M. S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ureter metastatic castration-resistant prostate cancer: a case report
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Ureter metastatic castration-resistant prostate cancer: a case report
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Ureter metastatic castration-resistant prostate cancer: a case report
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey